Gastrin peptide immunogenic composition
Inventors
Mudde, Geert Cornelius • Broome, Paul Christopher • Jacobs, Frederick William • Langer, Christof
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix; and b. a gastrin-17 peptide immunogen linked to a second peptidic alpha-helix coiled to the first alpha-helix, which peptide immunogen is any of (i) human gastrin-17 comprising the amino acid sequence of SEQ ID 1, or a fragment thereof comprising the amino acid sequence of SEQ ID 2, or at least the 4 N-terminal amino acids of SEQ ID 2; (ii) an analog of (i), preferably of rhesus monkey or murine origin; and/or (iii) a functionally active variant of any of (i) or (ii), with one, two, three or four point mutations in the amino acid sequence of SEQ ID 2. The invention further provides a kit for producing such immunogenic composition, a vaccine comprising such immunogenic composition and its medical use, such as for treating gastrin dependent diseases.
Core Innovation
The invention provides an immunogenic composition that combines a directed adjuvant and a gastrin-17 peptide immunogen for inducing an immune response against gastrin-17. The directed adjuvant comprises at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix. The anti-CD32 moiety specifically binds CD32 and is selected from antibodies, antibody fragments, proteins, or peptides.
The composition further comprises a gastrin-17 peptide immunogen linked to a second peptidic alpha-helix coiled to the first alpha-helix. The gastrin-17 peptide immunogen comprises an amino acid sequence of SEQ ID NOS: 1, 6, 8, or 9, or the peptide immunogen of SEQ ID NO:10. The first and second peptidic alpha-helices are repeats of matching coil repeat sequences selected from the group consisting of SEQ ID NOs: 14, 16, 18, 21, 24, 27, 30, and 33.
In the described system, the directed adjuvant and the gastrin-17 immunogen are arranged using alpha-helix coiled-coil pairing. Helix-coil repeat motifs are stated to provide high-affinity coiled-coil pairing with stated Kd thresholds. The TLR9 ligand is a TLR9 agonist selected from CpG oligodeoxynucleotide class A, B, and C, with the intent to drive Th1-promoting immune polarization.
Claims Coverage
The independent claim covers an immunogenic composition with two main inventive parts: a directed adjuvant that targets CD32 and includes a TLR9 agonist and a first peptidic alpha-helix, and a gastrin-17 peptide immunogen linked to a second matching peptidic alpha-helix coiled to the first helix. The claim further constrains the immunogen to specific SEQ ID-defined gastrin-17 peptide options and constrains the helix pairing to specified coil repeat sequences.
Directed adjuvant with anti-CD32 linked to a TLR9 agonist and a first alpha-helix
A directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix, wherein the anti-CD32 moiety specifically binds CD32 and is selected from antibodies, antibody fragments, proteins, or peptides, and the TLR9 ligand is a TLR9 agonist selected from CpG oligodeoxynucleotide class A, B, and C.
Gastrin-17 peptide immunogen linked to a second matching alpha-helix coiled to the first
A gastrin-17 peptide immunogen linked to a second peptidic alpha-helix coiled to the first alpha-helix, wherein the peptide immunogen comprises the amino acid sequence of SEQ ID NOS: 1, 6, 8, or 9; or the peptide immunogen of SEQ ID NO:10.
Matching coil repeat sequences for helix coiled pairing
The first and second peptidic alpha-helices are repeats of matching coil repeat sequences selected from the group consisting of SEQ ID NOs: 14, 16, 18, 21, 24, 27, 30, and 33.
Overall, the independent claim centers on coupling a CD32-targeting directed adjuvant to a gastrin-17 peptide immunogen linked by coiled-coil alpha-helix pairing. Claim coverage is grounded in specific SEQ ID-defined gastrin-17 peptide sequences and specified coil repeat sequences that govern matching alpha-helix repeats.
Stated Advantages
Induces an immunogenic response against gastrin-17 using a directed adjuvant combined with a coiled-coil linked gastrin-17 peptide immunogen.
Stated to provide high-affinity coiled-coil pairing with stated Kd thresholds.
TLR9 agonist use is stated to drive Th1-promoting immune polarization.
Reported induction of IgG against G17 components and reported cross-reactivity to human G17 in experimental examples.
Reported weight/appetite effects suggesting obesity control.
Reported indications for gastrin-dependent cancers, including pancreatic cancer.
Documented Applications
Cancer and other gastrin-dependent conditions listed in the provided claim-derived context: pancreatic cancer, gastric ulcer, GERD, end-stage renal failure (ESRF), and obesity.
Experimental use in animals including mice and cynomolgus monkeys, with reported IgG induction against G17 components and cross-reactivity to human G17.
Interested in licensing this patent?